Clinical Trials Insight: 700020639
Phase of Trial: Phase I
Latest Information Update: 03 Nov 2010
At a glance
- Drugs CX 157 (Primary)
- Indications Anxiety; Depressive disorders
- Focus Adverse reactions
- Sponsors CeNeRx BioPharma
- 03 Nov 2010 Results reported in CeNeRx BioPharma media release.
- 07 Dec 2009 According to a CeNeRx BioPharma media release CX 157 is safe and well tolerated.
- 16 Jan 2008 Status change from initiated to completed, from a CeNeRx Biopharma media release.